-Tomohide Tamura Researcher Activity Profile

Research Author Detailed Information 

Tomohide Tamura Publication Rate By Year

Tomohide Tamura has published 1 paper(s) in 2002, 1 paper(s) in 2006, 19 paper(s) in 2007, 5 paper(s) in 2008, for a total of 26 research publications in total.

Tomohide T Tamura Author Information

LAST NAME: tamura

FIRST NAME: tomohide

INITIALS: T

AFFILIATION:

Papers

Tomohide Tamura's Publication Record

1. A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with lung cancer. Year Published: 2007
Divisions of Thoracic Oncology and Internal Medicine, National Cancer Center Hospital, Tokyo, Japan.
2. Concurrent chemoradiotherapy for limited-disease small cell lung cancer in elderly patients aged 75 years or older. Year Published: 2007
Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
3. Phase I study of cisplatin analogue nedaplatin, paclitaxel, and thoracic radiotherapy for unresectable stage III non-small cell lung cancer. Year Published: 2007
Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan. isekine@ncc.go.jp
4. Localization of a human lung adenocarcinoma susceptibility locus, possibly syntenic to the mouse Pas1 locus, in the vicinity of the D12S1034 locus on chromosome 12p11.2-p12.1. Year Published: 2002
Biology Division, National Cancer Center Research Institute, 1-1,Tsukiji 5-chome, Chuo-ku, Tokyo 104-0045, Japan.
5. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Year Published: 2006
Shien-Lab, Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
6. Prognostic factors for malignant pericardial effusion treated by pericardial drainage in solid-malignancy patients. Year Published: 2007
Division of Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan. kyonemor@ncc.go.jp
7. Serum total bilirubin as a predictive factor for severe neutropenia in lung cancer patients treated with cisplatin and irinotecan. Year Published: 2007
Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo, Japan.
8. Genes regulating the sensitivity of solid tumor cell lines to cytotoxic agents: a literature review. Year Published: 2007
Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan. isekine@ncc.go.jp
9. Effect of platinum combined with irinotecan or paclitaxel against large cell neuroendocrine carcinoma of the lung. Year Published: 2007
Divisions of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan.
10. Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non small cell lung cancer treated with gefitinib. Year Published: 2007
Division of Internal Medicine, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
11. Prognostic factors for malignant pericardial effusion treated by pericardial drainage in solid-malignancy patients. Year Published: 2007
Division of Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan. kyonemor@ncc.go.jp
12. Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non small cell lung cancer treated with gefitinib. Year Published: 2007
Division of Internal Medicine, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
13. Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors. Year Published: 2007
Division of Internal Medicine, National Cancer Center Hospital, 5-1-1, Tsukiji Chuo-ku, Tokyo, 104-0045, Japan, ttamura@ncc.go.jp.
14. Genetic Variations and Frequencies of Major Haplotypes in SLCO1B1 Encoding the Transporter OATP1B1 in Japanese Subjects: SLCO1B1(*)17 is More Prevalent Than (*)15. Year Published: 2007
Project Team for Pharmacogenetics, National Institute of Health Sciences.
15. Genetic Variations of VDR/NR1I1 Encoding Vitamin D Receptor in a Japanese Population. Year Published: 2007
Project Team for Pharmacogenetics, National Institute of Health Sciences.
16. Genetic variations and frequencies of major haplotypes in SLCO1B1 encoding the transporter OATP1B1 in Japanese subjects: SLCO1B1*17 is more prevalent than *15. Year Published: 2007
Project Team for Pharmacogenetics, National Institute of Health Sciences, Tokyo, Japan.
17. Genetic variations of VDR/NR1I1 encoding vitamin D receptor in a Japanese population. Year Published: 2007
Project Team for Pharmacogenetics, National Institute of Health Sciences, Tokyo, Japan.
18. Genetic variations and frequencies of major haplotypes in SLCO1B1 encoding the transporter OATP1B1 in Japanese subjects: SLCO1B1*17 is more prevalent than *15. Year Published: 2007
Project Team for Pharmacogenetics, National Institute of Health Sciences, Tokyo, Japan.
19. Genetic variations of VDR/NR1I1 encoding vitamin D receptor in a Japanese population. Year Published: 2007
Project Team for Pharmacogenetics, National Institute of Health Sciences, Tokyo, Japan.
20. Prognostic factors for malignant pericardial effusion treated by pericardial drainage in solid-malignancy patients. Year Published: 2007
Division of Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan. kyonemor@ncc.go.jp
21. [Future directions of anticancer drug development in Japan.] Year Published: 2008
Urology, University of Tsukuba.
22. Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors. Year Published: 2008
Division of Internal Medicine, National Cancer Center Hospital, Chuo-ku, Tokyo, 104-0045, Japan, tshimizu@nara.med.kindai.ac.jp.
23. Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors. Year Published: 2007
Division of Internal Medicine, National Cancer Center Hospital, 5-1-1, Tsukiji Chuo-ku, Tokyo 104-0045, Japan.
24. Influence of Previous Chemotherapy on the Efficacy of Subsequent Docetaxel Therapy in Advanced Non-small Cell Lung Cancer Patients. Year Published: 2008
Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
25. Influence of previous chemotherapy on the efficacy of subsequent docetaxel therapy in advanced non-small cell lung cancer patients. Year Published: 2008
Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
26. [Future directions of anticancer drug development in Japan] Year Published: 2008
Urology, University of Tsukuba.